PODD

InsuletF

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$205.00

+43.9% vs current

Most likely

Base case

50%

Probability

Target price

$172.00

+20.8% vs current

B-

Bear case

25%

Probability

Target price

$130.00

-8.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

News flow is earnings-heavy and operationally positive, but the market reaction has been less supportive than the print itself. The anchor close was $160.4 on 2026-05-07, while live price data showed PODD at $154.16 on 2026-05-08, implying that the T+3 reaction remained weak even after the revenue beat and raised outlook. Trusted follow-up coverage emphasized the raised 2026 revenue view and international Omnipod strength, while available analyst-revision snippets pointed to lower price targets rather than a broad post-print upgrade cycle. Peer context is now anchored to diabetes-technology comparators rather than broad health-care-services names, but the memo remains tentative because direct public pure-play comps are limited and Insulet's valuation still depends on product-cycle execution. No usable social dataset was provided, so confidence should rest mainly on filings and company materials.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-05-06catalystQ1 beat-and-raise confirmed in earnings releaseMedium impact

Insulet reported Q1 2026 revenue of $761.7 million, up 33.9%, with adjusted EPS of $1.42, exceeded its prior constant-currency growth guide, and raised FY2026 total revenue growth guidance to 21%-23% from 20%-22% [#8-K-2026-05-06].

2026-06-30catalystInternational Omnipod growth and algorithm rollout remain the main operating follow-throughHigh impact

International Omnipod revenue grew 59.4% reported and 45.2% in constant currency; the company also highlighted launches in five Middle East countries and a broader Omnipod 5 algorithm rollout expected in the coming weeks, which supports continued installed-base expansion [#8-K-2026-05-06].

2027-12-31eventEVOLVE pivotal study could extend type 2 diabetes platform optionalityHigh impact

Management said the first participant was enrolled in the EVOLVE pivotal study for a fully closed-loop AID system for adults with type 2 diabetes, supporting a planned 510(k) filing in 2027 [#8-K-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology